Table of Contents

1 Report Business Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Phase I - IV Clinical Development Services Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
  • 1.2.2 Early Phase
  • 1.2.3 Phase II-III
  • 1.2.4 Phase IIIb-IV
• 1.3 Market by Application
  • 1.3.1 Global Phase I - IV Clinical Development Services Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
  • 1.3.2 Pharmaceutical Companies
  • 1.3.3 Medical Device Companies
  • 1.3.4 Contract Research Organizations
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Phase I - IV Clinical Development Services Market Perspective (2017-2028)
• 2.2 Phase I - IV Clinical Development Services Growth Trends by Region
  • 2.2.1 Phase I - IV Clinical Development Services Market Size by Region: 2017 VS 2021 VS 2028
  • 2.2.2 Phase I - IV Clinical Development Services Historic Market Size by Region (2017-2022)
  • 2.2.3 Phase I - IV Clinical Development Services Forecasted Market Size by Region (2023-2028)
• 2.3 Phase I - IV Clinical Development Services Market Dynamics
  • 2.3.1 Phase I - IV Clinical Development Services Industry Trends
  • 2.3.2 Phase I - IV Clinical Development Services Market Drivers
  • 2.3.3 Phase I - IV Clinical Development Services Market Challenges
  • 2.3.4 Phase I - IV Clinical Development Services Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Phase I - IV Clinical Development Services Players by Revenue
  • 3.1.1 Global Top Phase I - IV Clinical Development Services Players by Revenue (2017-2022)
  • 3.1.2 Global Phase I - IV Clinical Development Services Revenue Market Share by Players (2017-2022)
• 3.2 Global Phase I - IV Clinical Development Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 3.3 Players Covered: Ranking by Phase I - IV Clinical Development Services Revenue
• 3.4 Global Phase I - IV Clinical Development Services Market Concentration Ratio
  • 3.4.1 Global Phase I - IV Clinical Development Services Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Phase I - IV Clinical Development Services Revenue in 2021
• 3.5 Phase I - IV Clinical Development Services Key Players Head office and Area Served
• 3.6 Key Players Phase I - IV Clinical Development Services Product Solution and Service
• 3.7 Date of Enter into Phase I - IV Clinical Development Services Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Phase I - IV Clinical Development Services Breakdown Data by Type

• 4.1 Global Phase I - IV Clinical Development Services Historic Market Size by Type (2017-2022)
• 4.2 Global Phase I - IV Clinical Development Services Forecasted Market Size by Type (2023-2028)

5 Phase I - IV Clinical Development Services Breakdown Data by Application

• 5.1 Global Phase I - IV Clinical Development Services Historic Market Size by Application (2017-2022)
• 5.2 Global Phase I - IV Clinical Development Services Forecasted Market Size by Application (2023-2028)

6 North America

• 6.1 North America Phase I - IV Clinical Development Services Market Size (2017-2028)
• 6.2 North America Phase I - IV Clinical Development Services Market Size by Type
  • 6.2.1 North America Phase I - IV Clinical Development Services Market Size by Type (2017-2022)
  • 6.2.2 North America Phase I - IV Clinical Development Services Market Size by Type (2023-2028)
  • 6.2.3 North America Phase I - IV Clinical Development Services Market Share by Type (2017-2028)
• 6.3 North America Phase I - IV Clinical Development Services Market Size by Application
  • 6.3.1 North America Phase I - IV Clinical Development Services Market Size by Application (2017-2022)
  • 6.3.2 North America Phase I - IV Clinical Development Services Market Size by Application (2023-2028)
  • 6.3.3 North America Phase I - IV Clinical Development Services Market Share by Application (2017-2028)
• 6.4 North America Phase I - IV Clinical Development Services Market Size by Country
  • 6.4.1 North America Phase I - IV Clinical Development Services Market Size by Country (2017-2022)
  • 6.4.2 North America Phase I - IV Clinical Development Services Market Size by Country (2023-2028)
  • 6.4.3 United States
  • 6.4.4 Canada

7 Europe

• 7.1 Europe Phase I - IV Clinical Development Services Market Size (2017-2028)
• 7.2 Europe Phase I - IV Clinical Development Services Market Size by Type
  • 7.2.1 Europe Phase I - IV Clinical Development Services Market Size by Type (2017-2022)
  • 7.2.2 Europe Phase I - IV Clinical Development Services Market Size by Type (2023-2028)
  • 7.2.3 Europe Phase I - IV Clinical Development Services Market Share by Type (2017-2028)
• 7.3 Europe Phase I - IV Clinical Development Services Market Size by Application
  • 7.3.1 Europe Phase I - IV Clinical Development Services Market Size by Application (2017-2022)
  • 7.3.2 Europe Phase I - IV Clinical Development Services Market Size by Application (2023-2028)
  • 7.3.3 Europe Phase I - IV Clinical Development Services Market Share by Application (2017-2028)
• 7.4 Europe Phase I - IV Clinical Development Services Market Size by Country
  • 7.4.1 Europe Phase I - IV Clinical Development Services Market Size by Country (2017-2022)
  • 7.4.2 Europe Phase I - IV Clinical Development Services Market Size by Country (2023-2028)
  • 7.4.3 Germany
  • 7.4.4 France
  • 7.4.5 U.K.
  • 7.4.6 Italy
  • 7.4.7 Russia
  • 7.4.8 Nordic Countries

8 Asia-Pacific

• 8.1 Asia-Pacific Phase I - IV Clinical Development Services Market Size (2017-2028)
• 8.2 Asia-Pacific Phase I - IV Clinical Development Services Market Size by Type
  • 8.2.1 Asia-Pacific Phase I - IV Clinical Development Services Market Size by Type (2017-2022)
  • 8.2.2 Asia-Pacific Phase I - IV Clinical Development Services Market Size by Type (2023-2028)
  • 8.2.3 Asia-Pacific Phase I - IV Clinical Development Services Market Share by Type (2017-2028)
• 8.3 Asia-Pacific Phase I - IV Clinical Development Services Market Size by Application
  • 8.3.1 Asia-Pacific Phase I - IV Clinical Development Services Market Size by Application (2017-2022)
  • 8.3.2 Asia-Pacific Phase I - IV Clinical Development Services Market Size by Application (2023-2028)
  • 8.3.3 Asia-Pacific Phase I - IV Clinical Development Services Market Share by Application (2017-2028)
• 8.4 Asia-Pacific Phase I - IV Clinical Development Services Market Size by Region
  • 8.4.1 Asia-Pacific Phase I - IV Clinical Development Services Market Size by Region (2017-2022)
  • 8.4.2 Asia-Pacific Phase I - IV Clinical Development Services Market Size by Region (2023-2028)
  • 8.4.3 China
  • 8.4.4 Japan
  • 8.4.5 South Korea
  • 8.4.6 Southeast Asia
  • 8.4.7 India
  • 8.4.8 Australia

9 Latin America

• 9.1 Latin America Phase I - IV Clinical Development Services Market Size (2017-2028)
• 9.2 Latin America Phase I - IV Clinical Development Services Market Size by Type
  • 9.2.1 Latin America Phase I - IV Clinical Development Services Market Size by Type (2017-2022)
  • 9.2.2 Latin America Phase I - IV Clinical Development Services Market Size by Type (2023-2028)
  • 9.2.3 Latin America Phase I - IV Clinical Development Services Market Share by Type (2017-2028)
• 9.3 Latin America Phase I - IV Clinical Development Services Market Size by Application
  • 9.3.1 Latin America Phase I - IV Clinical Development Services Market Size by Application (2017-2022)
  • 9.3.2 Latin America Phase I - IV Clinical Development Services Market Size by Application (2023-2028)
  • 9.3.3 Latin America Phase I - IV Clinical Development Services Market Share by Application (2017-2028)
• 9.4 Latin America Phase I - IV Clinical Development Services Market Size by Country
  • 9.4.1 Latin America Phase I - IV Clinical Development Services Market Size by Country (2017-2022)
  • 9.4.2 Latin America Phase I - IV Clinical Development Services Market Size by Country (2023-2028)
  • 9.4.3 Mexico
  • 9.4.4 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Phase I - IV Clinical Development Services Market Size (2017-2028)
• 10.2 Middle East & Africa Phase I - IV Clinical Development Services Market Size by Type
  • 10.2.1 Middle East & Africa Phase I - IV Clinical Development Services Market Size by Type (2017-2022)
  • 10.2.2 Middle East & Africa Phase I - IV Clinical Development Services Market Size by Type (2023-2028)
  • 10.2.3 Middle East & Africa Phase I - IV Clinical Development Services Market Share by Type (2017-2028)
• 10.3 Middle East & Africa Phase I - IV Clinical Development Services Market Size by Application
  • 10.3.1 Middle East & Africa Phase I - IV Clinical Development Services Market Size by Application (2017-2022)
  • 10.3.2 Middle East & Africa Phase I - IV Clinical Development Services Market Size by Application (2023-2028)
  • 10.3.3 Middle East & Africa Phase I - IV Clinical Development Services Market Share by Application (2017-2028)
• 10.4 Middle East & Africa Phase I - IV Clinical Development Services Market Size by Country
  • 10.4.1 Middle East & Africa Phase I - IV Clinical Development Services Market Size by Country (2017-2022)
  • 10.4.2 Middle East & Africa Phase I - IV Clinical Development Services Market Size by Country (2023-2028)
  • 10.4.3 Turkey
  • 10.4.4 Saudi Arabia
  • 10.4.5 UAE

11 Key Players Profiles

• 11.1 Syneos Health
  • 11.1.1 Syneos Health Company Details
  • 11.1.2 Syneos Health Business Overview
  • 11.1.3 Syneos Health Phase I - IV Clinical Development Services Introduction
  • 11.1.4 Syneos Health Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.1.5 Syneos Health Recent Developments
• 11.2 PPD
  • 11.2.1 PPD Company Details
  • 11.2.2 PPD Business Overview
  • 11.2.3 PPD Phase I - IV Clinical Development Services Introduction
  • 11.2.4 PPD Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.2.5 PPD Recent Developments
• 11.3 GVI CDS
  • 11.3.1 GVI CDS Company Details
  • 11.3.2 GVI CDS Business Overview
  • 11.3.3 GVI CDS Phase I - IV Clinical Development Services Introduction
  • 11.3.4 GVI CDS Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.3.5 GVI CDS Recent Developments
• 11.4 Parexel
  • 11.4.1 Parexel Company Details
  • 11.4.2 Parexel Business Overview
  • 11.4.3 Parexel Phase I - IV Clinical Development Services Introduction
  • 11.4.4 Parexel Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.4.5 Parexel Recent Developments
• 11.5 Clinical Leader
  • 11.5.1 Clinical Leader Company Details
  • 11.5.2 Clinical Leader Business Overview
  • 11.5.3 Clinical Leader Phase I - IV Clinical Development Services Introduction
  • 11.5.4 Clinical Leader Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.5.5 Clinical Leader Recent Developments
• 11.6 Thermo Fisher Scientific
  • 11.6.1 Thermo Fisher Scientific Company Details
  • 11.6.2 Thermo Fisher Scientific Business Overview
  • 11.6.3 Thermo Fisher Scientific Phase I - IV Clinical Development Services Introduction
  • 11.6.4 Thermo Fisher Scientific Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.6.5 Thermo Fisher Scientific Recent Developments
• 11.7 LabCorp
  • 11.7.1 LabCorp Company Details
  • 11.7.2 LabCorp Business Overview
  • 11.7.3 LabCorp Phase I - IV Clinical Development Services Introduction
  • 11.7.4 LabCorp Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.7.5 LabCorp Recent Developments
• 11.8 Worldwide Clinical Trial
  • 11.8.1 Worldwide Clinical Trial Company Details
  • 11.8.2 Worldwide Clinical Trial Business Overview
  • 11.8.3 Worldwide Clinical Trial Phase I - IV Clinical Development Services Introduction
  • 11.8.4 Worldwide Clinical Trial Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.8.5 Worldwide Clinical Trial Recent Developments
• 11.9 CROS NT
  • 11.9.1 CROS NT Company Details
  • 11.9.2 CROS NT Business Overview
  • 11.9.3 CROS NT Phase I - IV Clinical Development Services Introduction
  • 11.9.4 CROS NT Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.9.5 CROS NT Recent Developments
• 11.10 Dynakin
  • 11.10.1 Dynakin Company Details
  • 11.10.2 Dynakin Business Overview
  • 11.10.3 Dynakin Phase I - IV Clinical Development Services Introduction
  • 11.10.4 Dynakin Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.10.5 Dynakin Recent Developments
• 11.11 Rho, Inc.
  • 11.11.1 Rho, Inc. Company Details
  • 11.11.2 Rho, Inc. Business Overview
  • 11.11.3 Rho, Inc. Phase I - IV Clinical Development Services Introduction
  • 11.11.4 Rho, Inc. Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.11.5 Rho, Inc. Recent Developments
• 11.12 Synteract
  • 11.12.1 Synteract Company Details
  • 11.12.2 Synteract Business Overview
  • 11.12.3 Synteract Phase I - IV Clinical Development Services Introduction
  • 11.12.4 Synteract Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.12.5 Synteract Recent Developments
• 11.13 ICBio CRO
  • 11.13.1 ICBio CRO Company Details
  • 11.13.2 ICBio CRO Business Overview
  • 11.13.3 ICBio CRO Phase I - IV Clinical Development Services Introduction
  • 11.13.4 ICBio CRO Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.13.5 ICBio CRO Recent Developments
• 11.14 Sofpromed
  • 11.14.1 Sofpromed Company Details
  • 11.14.2 Sofpromed Business Overview
  • 11.14.3 Sofpromed Phase I - IV Clinical Development Services Introduction
  • 11.14.4 Sofpromed Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.14.5 Sofpromed Recent Developments
• 11.15 Profil
  • 11.15.1 Profil Company Details
  • 11.15.2 Profil Business Overview
  • 11.15.3 Profil Phase I - IV Clinical Development Services Introduction
  • 11.15.4 Profil Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.15.5 Profil Recent Developments
• 11.16 ICON Plc
  • 11.16.1 ICON Plc Company Details
  • 11.16.2 ICON Plc Business Overview
  • 11.16.3 ICON Plc Phase I - IV Clinical Development Services Introduction
  • 11.16.4 ICON Plc Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.16.5 ICON Plc Recent Developments
• 11.17 Clinipace
  • 11.17.1 Clinipace Company Details
  • 11.17.2 Clinipace Business Overview
  • 11.17.3 Clinipace Phase I - IV Clinical Development Services Introduction
  • 11.17.4 Clinipace Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.17.5 Clinipace Recent Developments
• 11.18 OCT Clinical
  • 11.18.1 OCT Clinical Company Details
  • 11.18.2 OCT Clinical Business Overview
  • 11.18.3 OCT Clinical Phase I - IV Clinical Development Services Introduction
  • 11.18.4 OCT Clinical Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.18.5 OCT Clinical Recent Developments
• 11.19 EPS Group
  • 11.19.1 EPS Group Company Details
  • 11.19.2 EPS Group Business Overview
  • 11.19.3 EPS Group Phase I - IV Clinical Development Services Introduction
  • 11.19.4 EPS Group Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.19.5 EPS Group Recent Developments
• 11.20 Beijing Sun-novo Pharmaceutical Research
  • 11.20.1 Beijing Sun-novo Pharmaceutical Research Company Details
  • 11.20.2 Beijing Sun-novo Pharmaceutical Research Business Overview
  • 11.20.3 Beijing Sun-novo Pharmaceutical Research Phase I - IV Clinical Development Services Introduction
  • 11.20.4 Beijing Sun-novo Pharmaceutical Research Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.20.5 Beijing Sun-novo Pharmaceutical Research Recent Developments
• 11.21 Dmedglobal
  • 11.21.1 Dmedglobal Company Details
  • 11.21.2 Dmedglobal Business Overview
  • 11.21.3 Dmedglobal Phase I - IV Clinical Development Services Introduction
  • 11.21.4 Dmedglobal Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.21.5 Dmedglobal Recent Developments
• 11.22 WuXi AppTec
  • 11.22.1 WuXi AppTec Company Details
  • 11.22.2 WuXi AppTec Business Overview
  • 11.22.3 WuXi AppTec Phase I - IV Clinical Development Services Introduction
  • 11.22.4 WuXi AppTec Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.22.5 WuXi AppTec Recent Developments
• 11.23 Elixir Clinical Research
  • 11.23.1 Elixir Clinical Research Company Details
  • 11.23.2 Elixir Clinical Research Business Overview
  • 11.23.3 Elixir Clinical Research Phase I - IV Clinical Development Services Introduction
  • 11.23.4 Elixir Clinical Research Revenue in Phase I - IV Clinical Development Services Business (2017-2022)
  • 11.23.5 Elixir Clinical Research Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Author Details

Summary:

Market Analysis and Insights: Global Phase I - IV Clinical Development Services Market
The global Phase I - IV Clinical Development Services market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Early Phase accounting for % of the Phase I - IV Clinical Development Services global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Pharmaceutical Companies segment is altered to an % CAGR throughout this forecast period.
China Phase I - IV Clinical Development Services market size is valued at US$ million in 2021, while the North America and Europe Phase I - IV Clinical Development Services are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Phase I - IV Clinical Development Services landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Phase I - IV Clinical Development Services market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Phase I - IV Clinical Development Services market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Phase I - IV Clinical Development Services market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Phase I - IV Clinical Development Services market.
Impact of Covid-19 Outbreak
This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.
Segmental Analysis
The report has been segmented into product and application segments. The researchers have documented all the products present today in the Phase I - IV Clinical Development Services market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.
Phase I - IV Clinical Development Services Breakdown Data by Type
Early Phase
Phase II-III
Phase IIIb-IV
Phase I - IV Clinical Development Services Breakdown Data by Application
Pharmaceutical Companies
Medical Device Companies
Contract Research Organizations
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Competitive Landscape
This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:
Syneos Health
PPD
GVI CDS
Parexel
Clinical Leader
Thermo Fisher Scientific
LabCorp
Worldwide Clinical Trial
CROS NT
Dynakin
Rho, Inc.
Synteract
ICBio CRO
Sofpromed
Profil
ICON Plc
Clinipace
OCT Clinical
EPS Group
Beijing Sun-novo Pharmaceutical Research
Dmedglobal
WuXi AppTec
Elixir Clinical Research
Frequently Asked Questions
What factors will challenge the Phase I - IV Clinical Development Services market growth?
Which end-use segment will expand at the fastest CAGR in the Phase I - IV Clinical Development Services market?
Which are the emerging players in the Phase I - IV Clinical Development Services market?
How concentrated is the Phase I - IV Clinical Development Services market?
Which factors are positively contributing to the Phase I - IV Clinical Development Services market growth?
Which are the novel product innovations in the Phase I - IV Clinical Development Services market?
Which product segment will emerge as the most lucrative in the Phase I - IV Clinical Development Services market?
Which factors are increasing the competition in the Phase I - IV Clinical Development Services market?
Which are the strategic measures taken by the Phase I - IV Clinical Development Services industry players?
Which region will witness inactive growth during the forecast period?
What key trends are likely to emerge in the Phase I - IV Clinical Development Services market in the coming years?